Beijing Yisheng Biotechnology
Pluripotent stem cell therapies for diabetes treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
Beijing Yisheng Biotechnology Co., Ltd., also known as Essentia BioSciences, is a biopharmaceutical firm focused on developing cell-based drugs from pluripotent stem cells. The company specializes in creating pancreatic islet therapies to treat diseases like type 1 diabetes.
The company's core team includes talent from Peking University, Tsinghua University, and the University of Cambridge. The company has established a research and production center in Beijing and a wholly-owned research laboratory in Cambridge, UK, called ACESO BIOSCIENCES. In March 2022, Yisheng Biotechnology established a presence in the Daxing part of the Beijing Daxing International Airport Economic Zone. The production facility in this zone, expected to be operational in July 2024, will support the preclinical research of its primary drug candidate, ESN5800. ESN5800 is a pluripotent stem cell-differentiated islet cell therapy for type 1 diabetes, with Phase 1 clinical trials planned for China and the UK.
The company has received several awards, including from the HICOOL Global Entrepreneur Summit and the 'Golden Panda' Global Innovation and Entrepreneurship Competition in 2021. In 2022, it was recognized as a leading enterprise founded by talents in the "New National Gate" Project of the Daxing district.
Keywords: biopharmaceutical, cell therapy, pluripotent stem cells, regenerative medicine, diabetes treatment, pancreatic islet therapy, ESN5800, iPSC, preclinical research, clinical trials, ACESO BIOSCIENCES, cell drugs, type 1 diabetes, stem cell differentiation, GMP-grade iPSC bank